Biologic Therapy in Head and Neck Cancer: A Road with Hurdles

Table 3

Targeted agents under investigation in SCCHN.

Trial phase	Compound	Target/mechanism of action	Disease setting	Administration	Associated treatment
Randomized phase lll	INGN 201	p53 gene	R/M	iv	PF
	Bevacizumab	VEGF	R/M	iv	platin-based doublet
	Reovirus serotype 3 dearing	Virus	R/M platinum refractory	iv	Placebo
Phase ll	Temsirolimus	mTOR	R/M	iv	Carbo + paclitaxel
	PX-866	Phosphoinositide-3-kinase	Solid tumors	po	T
	Everolimus	mTOR	R/M	po	(T)
	Everolimus	mTOR	LA	po	Carbo + paclitaxel
	BBI608	Cancer stem cells	Advanced malignancies	po	Paclitaxel
	Sorafenib	CRAF; BRAF; c-KIT; FLT-3; VEGFR-2/3; PDGFR-𝛽	R/M	po
	Cediranib	VEGFR-2/3	R/M	po
	Tadalafil	Phosphodiesterase-5 inhibitor	R/M	po
	Fostamatinib	syk	Solid tumors	po
	LY2523355	Mitotic kinesin Eg5 inhibitor	Solid tumors	iv
	Vorinostat	HDACi	R/M	po	Capecitabine
	Gossypol	Bcl-2	R/M	po	T
	Pazopanib	VEGFRl-3; PDGFR𝛼/𝛽; FGFR1,3,4; KIT; RET	R/M	po
	ACE-041	ALK1	R/M second line	sc
	Axitinib	VEGFRl-3; c-KIT; PDGFR	R/M	po
	Dacomitinib	Pan-ERBB inhibitor	R/M platinum refractory	po
Phase l	MAGE-A3/HPV 16	Vaccine	R/M
	MLN9708	Proteasome inhibitor	Solid tumors	po
	4SC-205	Mitotic kinesin Eg5 inhibitor	Advanced malignancies	po
	SAR566658	HuDS6 + DM4*	DS6-positive tumors	iv
	MEHD7945A	EGFR/HER3	Epithelial tumors	iv
	CUDC-101	HDACi; EGFR; HER2	LA	po	RT + P

RT: radiotherapy; T: docetaxel; P: cisplatin; HDACi: histone deacetylase inhibitor; LA: locoregionally advanced; R/M: recurrent/metastatic.
*Tumor-associated sialoglycotope CA6 (huDS6) conjugated to the cytotoxic maytansinoid DM4.
Syk: spleen tyrosine kinase; po: per os; iv: intravenously.
ALK1: activin receptor-like kinase 1 (ALK1).